209052-01-7

Usage

Uses

Used in Pharmaceutical Industry:
N6-Carbobenzyloxy-N2,N2-bis(carboxymethyl)lysine is used as a key component in the synthesis of nickel-chelating fluorinated lipids for protein monolayer crystallizations. This application is crucial for the study and understanding of protein structures, which can lead to the development of new drugs and therapies.
Used in Chemical Research:
As a white solid with specific chemical properties, N6-Carbobenzyloxy-N2,N2-bis(carboxymethyl)lysine can be utilized in various chemical research applications, potentially contributing to the advancement of chemical science and technology.

InChI:InChI=1/C18H24N2O8/c21-15(22)10-20(11-16(23)24)14(17(25)26)8-4-5-9-19-18(27)28-12-13-6-2-1-3-7-13/h1-3,6-7,14H,4-5,8-12H2,(H,19,27)(H,21,22)(H,23,24)(H,25,26)

Upstream product

• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 
• 79-08-3 bromoacetic acid 
• 32302-83-3 N-ε-benzyloxycarbonyl lysine 

Downstream Products

• 1279699-68-1 ε-benzyloxycarbonyl-α-dicarboxylmethyl-L-lysine-tris(aminohexyl-β-N-acetylgalactosamine) 

Relevant academic research and scientific papers

Intracellular Delivery of Functional Proteins and Native Drugs by Cell-Penetrating Poly(disulfide)s

The efficient delivery of bioactive compounds into cells is a major challenge in drug discovery. We report herein the development of novel methods for intracellular delivery of functional proteins (including antibodies) and native small-molecule drugs by

Multifunctional polymeric micelle for jointly conveying photosensitizer and gene editing system, preparation method of micelle and application of micelle

The invention discloses a multifunctional polymeric micelle for jointly conveying a photosensitizer and a gene editing system, a preparation method of the micelle and an application of the micelle. The multifunctional polymeric micelle is of a three-layer structure, a core is hydrophobic polycaprolactone for loading the photosensitizer, a middle layer is ligand NTA (nitrilotriacetic acid) which can be coupled with the gene editing system, and an outer layer is an iRGD-polyethylene glycol-polyaspartyl (butanediamine) positive polymer and can be combined with the middle layer through electrostatic interaction. The multifunctional polymer serves as a carrier, and can efficiently enter a tumor cell owing to targeting ability after loading the photosensitizer and the gene editing system, the micelle and the gene editing system are dissociated in a lysosome acid environment, the photosensitizer realizes photodynamic therapy after laser irradiation, the gene editing system knocks out expressed genes of Nrf2 and blocks expression of the Nrf2, and apoptosis of the tumor cell is promoted. The photosensitizer and the gene editing system jointly play a role, photodynamic therapy and gene therapy are simultaneously performed, and antitumor effects are greatly enhanced.

TREATING BLADDER TUMOR CELLS USING FIBRONECTIN ATTACHMENT PROTEIN AS A TARGET

Composition and methods are disclosed for utilizing microaggregation of FAP-containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor

Chelating agent, synthesis method and application thereof as well as chelate containing the same

The invention discloses a chelating agent, which has a structural general formula shown as the specification. The invention also discloses a chelate containing the chelating agent and metal ions, and a synthesis method of the chelating agent. The method includes: (1) synthesizing a precursor compound of the chelating agent by active ester method; (2) carrying out catalytic hydrogenation reaction to obtain the chelating agent. The chelating agent can be used as a radioactive imaging and therapy drug, a magnetic resonance imaging drug, selective chelation separate trivalent metal ions and the like. The chelating agent provided by the invention is a hexadentate ligand, has strong chelating ability with a lot of trivalent metal ions, and therefore has small dosage during chelate formation, and has reduced toxic and side effect when serving as a drugs, at the same time the chelating agent contains amino at the left end and can achieve connection with some biological target molecules, and can be used for preparation of various targeted drugs. The coordination reaction of the chelating agent and metal ions has mild conditions (usually at room temperature), and the drug preparation process is simplified. The preparation method of the chelating agent has the advantages of easily available raw materials and simple process, thus being easy for large-scale promotion.

Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes

The comprehensive structure-activity relationships of triantennary GalNAc conjugated ASOs for enhancing potency via ASGR mediated delivery to hepatocytes is reported. Seventeen GalNAc clusters were assembled from six distinct scaffolds and attached to ASOs. The resulting ASO conjugates were evaluated in ASGR binding assays, in primary hepatocytes, and in mice. Five structurally distinct GalNAc clusters were chosen for more extensive evaluation using ASOs targeting SRB-1, A1AT, FXI, TTR, and ApoC III mRNAs. GalNAc-ASO conjugates exhibited excellent potencies (ED50 0.5-2 mg/kg) for reducing the targeted mRNAs and proteins. This work culminated in the identification of a simplified tris-based GalNAc cluster (THA-GN3), which can be efficiently assembled using readily available starting materials and conjugated to ASOs using a solution phase conjugation strategy. GalNAc-ASO conjugates thus represent a viable approach for enhancing potency of ASO drugs in the clinic without adding significant complexity or cost to existing protocols for manufacturing oligonucleotide drugs.

COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION

The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.

COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION

The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (GHR).

COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION

Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

Affinity peptides

Fusion proteins and a process for their purification by means of metal chelate affinity chromatography on NTA resins are provided by this invention.